Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...

In early UK corporate news, GSK announced a buyback and upped its 2031 sales target. Here is what you need to know at the London market open: FTSE 100: called down 0.3% at 8,542.57 Hang Seng: down 1.0 ...

GSK's former head of vaccines R&D – Dr Emmanuel ... a vaccine against respiratory syncytial virus (RSV) infections. The London-based company was founded by venture capital firm Medicxi in ...

The lawsuit claims GlaxoSmithKline replaced Flovent with ... citing the Arizona Consumer Fraud Act, says that the London-based multinational company was motivated by greed when it discontinued ...

GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...

Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...

(Alliance News) - Stock prices in London were mixed on Wednesday afternoon, with a share price rise for GSK supporting the FTSE 100, though tariff worries continue to hang over equities.

London stocks nudged higher in early trade on Wednesday as investors mulled disappointing US tech results and continued to ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.

GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...